Analysts expect that Chromadex Corp (NASDAQ:CDXC) will post $9.80 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Chromadex’s earnings, with the lowest sales estimate coming in at $9.59 million and the highest estimate coming in at $10.00 million. Chromadex reported sales of $6.57 million in the same quarter last year, which would suggest a positive year over year growth rate of 49.2%. The company is scheduled to issue its next quarterly earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Chromadex will report full year sales of $46.88 million for the current financial year, with estimates ranging from $44.75 million to $49.00 million. For the next year, analysts forecast that the business will post sales of $80.55 million, with estimates ranging from $67.09 million to $94.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Chromadex.

Chromadex (NASDAQ:CDXC) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Chromadex had a negative return on equity of 90.20% and a negative net margin of 105.57%. The business had revenue of $9.07 million for the quarter, compared to analyst estimates of $9.21 million.

Several equities analysts have commented on the company. B. Riley reaffirmed a “buy” rating on shares of Chromadex in a report on Friday, March 8th. Zacks Investment Research raised Chromadex from a “sell” rating to a “hold” rating in a report on Wednesday, January 9th. Finally, HC Wainwright set a $7.00 price target on Chromadex and gave the company a “buy” rating in a report on Wednesday, January 23rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Chromadex currently has a consensus rating of “Hold” and an average target price of $6.00.

Shares of NASDAQ CDXC remained flat at $$3.95 during trading hours on Thursday. The company had a trading volume of 163,348 shares, compared to its average volume of 197,654. Chromadex has a fifty-two week low of $2.79 and a fifty-two week high of $5.00. The company has a quick ratio of 1.96, a current ratio of 2.53 and a debt-to-equity ratio of 0.01. The firm has a market cap of $218.38 million, a PE ratio of -6.48 and a beta of 1.09.

In other news, Director Stephen A. Block sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $3.52, for a total value of $35,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Kevin M. Farr acquired 6,725 shares of the stock in a transaction dated Thursday, March 14th. The stock was bought at an average price of $3.99 per share, for a total transaction of $26,832.75. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 17,425 shares of company stock valued at $65,726. Insiders own 10.26% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Resources Investment Advisors Inc. grew its stake in shares of Chromadex by 125.0% in the 4th quarter. Resources Investment Advisors Inc. now owns 9,000 shares of the company’s stock valued at $31,000 after purchasing an additional 5,000 shares during the period. Northern Trust Corp grew its stake in shares of Chromadex by 1.2% in the 4th quarter. Northern Trust Corp now owns 411,436 shares of the company’s stock valued at $1,412,000 after purchasing an additional 5,009 shares during the period. Tieton Capital Management LLC grew its stake in shares of Chromadex by 1.0% in the 4th quarter. Tieton Capital Management LLC now owns 1,092,465 shares of the company’s stock valued at $3,747,000 after purchasing an additional 11,220 shares during the period. Rhumbline Advisers grew its stake in shares of Chromadex by 53.3% in the 4th quarter. Rhumbline Advisers now owns 48,511 shares of the company’s stock valued at $166,000 after purchasing an additional 16,863 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Chromadex by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 346,723 shares of the company’s stock valued at $1,189,000 after purchasing an additional 17,361 shares during the period. Institutional investors own 17.24% of the company’s stock.

Chromadex Company Profile

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.

See Also: Gross Domestic Product (GDP)

Get a free copy of the Zacks research report on Chromadex (CDXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.